Tevogen Bio highlighted AI's role in drug development efficiency at the J.P. Morgan Healthcare Conference.
Quiver AI Summary
Tevogen Bio Holdings Inc., a clinical-stage biotech firm specializing in immunotherapy, discussed its advancements in artificial intelligence (AI) during the J.P. Morgan Healthcare Conference. The company emphasizes patient equity and the use of machine learning through its Tevogen.AI platform, which has led to significant cost and time savings in drug development. Dr. David Rhew from Microsoft and Tevogen's Mittul Mehta highlighted how AI is transforming drug discovery by rapidly identifying candidates that would have traditionally taken years. They also noted the increasing importance of using multimodal data for deeper insights and stressed the need for high-quality, clean datasets to ensure responsible AI use. Tevogen Bio aims to improve accessibility to innovative therapeutics, backed by positive clinical trial results and a solid patent portfolio.
Potential Positives
- Tevogen Bio is leveraging artificial intelligence and machine learning to enhance drug discovery processes, significantly reducing development time from potentially thousands of years to mere months.
- The company has obtained positive safety data from its proof-of-concept clinical trial, indicating progress in its therapeutic development.
- Tevogen Bio owns its key intellectual property assets, including granted and pending patents related to artificial intelligence, providing strong competitive advantages and potential for future innovations.
- Tevogen Bio’s commitment to patient equity and affordability in medical innovation reflects a forward-thinking approach that could improve market positioning and public perception.
Potential Negatives
- The press release emphasizes the reliance on AI and ML, which may raise concerns about the company's vulnerability to technology failures or inaccuracies that could impact drug development.
- The necessity of “clean” and “curated” data highlights potential risks regarding the quality and availability of data, which could hinder operational efficiency and innovation.
- The focus on patient equity and affordability may indicate prior issues related to access or cost that the company now feels the need to address, signaling potential vulnerabilities in its business model.
FAQ
What is Tevogen Bio?
Tevogen Bio is a clinical-stage biotech developing off-the-shelf, genetically unmodified T-cell therapies for infectious diseases and cancers.
How is Tevogen Bio using AI in drug development?
Tevogen Bio employs AI and machine learning to improve drug discovery efficiency, reducing traditional timelines significantly.
Who are the key speakers from the J.P. Morgan Healthcare Conference?
The discussion featured Dr. David Rhew from Microsoft and Mittul Mehta, Tevogen.AI's Chief Information Officer.
What are the benefits of multimodal data AI?
Multimodal data AI processes diverse data sources, revealing insights that can enhance drug candidate development and healthcare delivery.
How does Tevogen Bio ensure data quality for AI models?
Tevogen Bio focuses on creating curated datasets and emphasizes the need for clean, annotated data for effective AI applications.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$TVGN Insider Trading Activity
$TVGN insiders have traded $TVGN stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $TVGN stock by insiders over the last 6 months:
- NEAL FLOMENBERG (See Remarks) sold 1,078,600 shares for an estimated $1,747,332
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$TVGN Hedge Fund Activity
We have seen 26 institutional investors add shares of $TVGN stock to their portfolio, and 10 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- POLAR ASSET MANAGEMENT PARTNERS INC. removed 408,228 shares (-20.6%) from their portfolio in Q3 2024, for an estimated $150,391
- HGC INVESTMENT MANAGEMENT INC. added 223,077 shares (+inf%) to their portfolio in Q3 2024, for an estimated $82,181
- NORTHERN TRUST CORP added 104,820 shares (+inf%) to their portfolio in Q3 2024, for an estimated $38,615
- PORTLAND GLOBAL ADVISORS LLC removed 56,000 shares (-2.9%) from their portfolio in Q3 2024, for an estimated $20,630
- CITADEL ADVISORS LLC removed 48,398 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $17,829
- CANTOR FITZGERALD, L. P. removed 46,309 shares (-7.1%) from their portfolio in Q3 2024, for an estimated $17,060
- GOLDMAN SACHS GROUP INC added 36,606 shares (+inf%) to their portfolio in Q3 2024, for an estimated $13,485
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
WARREN, N.J., Jan. 23, 2025 (GLOBE NEWSWIRE) --
Tevogen Bio Holdings Inc.
(“Company” or “Tevogen Bio”) (Nasdaq:
TVGN
), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T-cell therapeutics for infectious diseases and cancers, today announced key insights from its recent fireside chat during the J.P. Morgan Healthcare Conference. Utilizing artificial intelligence (AI) and machine learning (ML) has been critical for Tevogen Bio, given its core commitment to patient equity. By applying ML through Tevogen.AI, the company has already achieved notable cost and time efficiencies, developments that could translate directly into savings for patients. The discussion featured Dr. David Rhew, Global Chief Medical Officer & VP of Healthcare at Microsoft (Nasdaq:
MSFT
), and Mittul Mehta, Chief Information Officer and Head of Tevogen.AI, who shared their vision for how AI is revolutionizing drug development and healthcare delivery.
Accelerating Drug Discovery
In the fireside chat, Dr. Rhew described how AI-driven modeling and simulation are drastically reducing the time required to identify and develop drug candidates. He provided an example where a computational task that previously may have taken “thousands of years” using traditional approaches was completed in a matter of months thanks to AI-powered tools. These breakthroughs, Dr. Rhew noted, illustrate a paradigm shift in what is now possible in the pharmaceutical research and development process.
The Rise of Generative AI and Multimodal Data
Both speakers emphasized that while generative AI has garnered widespread attention, next-generation approaches extend beyond simply creating text or images. According to Dr. Rhew, organizations are increasingly deploying multimodal data AI, which processes data from diverse sources, such as imaging, genomics, and electronic health records, to reveal novel insights. Generative AI then serves as a powerful query engine on top of these “foundation models,” enabling seamless interpretation and conversion of complex data into clinically relevant results and formats.
Ensuring Data Quality, Privacy, and Responsible AI
Speaking to Tevogen Bio’s AI developments, Mittul Mehta, Chief Information Officer and Head of Tevogen.AI, highlighted, “We are creating curated datasets, supported by wet-lab research, to fuel the creation of reliable foundational AI models." Dr. Rhew echoed the need for “clean” and “annotated” datasets, stating, “AI is like a powerful engine. It can take us anywhere, but it needs clean, curated data as fuel. Crude data won't work; it must be refined and properly annotated to be useful." Both speakers also stressed the importance of strong data governance and privacy-preserving techniques, such as federated learning and confidential compute, which enable secure collaboration on sensitive datasets without exposing proprietary information or intellectual property. Dr. Rhew underscored that responsible AI requires bias mitigation, transparency, and continuous oversight. Mr. Mehta commended Microsoft’s commitment to these principles, stating that responsible development practices are vital to ensuring equitable and safe adoption of AI technologies in healthcare.
“AI is the next industrial revolution and could be humanity’s greatest leap yet. I commend efforts similar to Stargate for their investment in forward-thinking and transformative technologies,” said Ryan Saadi, MD, MPH, Founder and CEO of Tevogen Bio. “Drug development will undoubtedly improve with the power of AI, but the key is to seamlessly bridge medical science and technology. As a biotech focused on pioneering through AI, we remain committed to advancing affordable medical innovation.”
About Tevogen Bio
Tevogen Bio is a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the significant unmet needs of large patient populations. Tevogen Bio Leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen Bio has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents, nine pending US and twelve ex-US pending patents, two of which are related to artificial intelligence.
Tevogen Bio is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen Bio’s leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation.
Contacts
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/8f6d82a7-ae1f-40ac-888f-dbd580e3af4b
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
